Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.39 |
| ▸ | CTSL | P07711 | 3/20 | 0.35 |
| ▸ | CTSB | P07858 | 3/20 | 0.35 |
| ▸ | CTSH | P09668 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1862554 | 1.00 | CTSK (0.39) | CTSKCTSLCTSBCTSHATM | |
| SCHEMBL1864711 | 0.98 | CTSK (0.36) | CTSKCTSLCTSBCTSHATM | |
| SCHEMBL14859918 | 0.92 | CTSK (0.31) | CTSKCTSSCPB2 | |
| SCHEMBL2023160 | 0.83 | PSEN1 (0.31) | — | |
| SCHEMBL2326663 | 0.83 | PSEN1 (0.31) | — | |
| SCHEMBL1870238 | 0.82 | CTSK (0.37) | CTSKCTSLCTSBCTSHATM | |
| SCHEMBL1861633 | 0.80 | ALOX5 (0.36) | CTSKCTSLCTSBCTSHATM | |
| SCHEMBL1859373 | 0.79 | CTSK (0.35) | CTSKCTSLCTSBCTSHATM | |
| SCHEMBL1863227 | 0.78 | CTSK (0.36) | CTSKCTSLCTSBCTSHATM | |
| SCHEMBL1861638 | 0.78 | CTSK (0.36) | CTSKCTSLCTSBCTSHATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | CTSK 1067/4885CTSL 1629/4885CTSB 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.